Vor Biopharma Inc
$ 15.90
-1.00%
26 Feb - close price
- Market Cap 666,809,000 USD
- Current Price $ 15.90
- High / Low $ 16.49 / 15.57
- Stock P/E N/A
- Book Value -246.54
- EPS -386.86
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.44 %
- ROE -1.25 %
- 52 Week High 65.80
- 52 Week Low 2.62
About
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$44.60
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-12 | 2025-05-07 | 2025-03-18 | 2024-11-05 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-07 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -121.6 | -251.24 | -0.26 | -0.44 | -0.4 | -0.41 | -0.45 | -0.39 | -0.49 | -0.45 | -0.43 | -0.52 |
| Estimated EPS | -0.1 | -0.2243 | -0.208 | -0.3067 | -0.4 | -0.42 | -0.38 | -0.5 | -0.47 | -0.43 | -0.38 | -0.6 |
| Surprise | -121.5 | -251.0157 | -0.052 | -0.1333 | 0 | 0.01 | -0.07 | 0.11 | -0.02 | -0.02 | -0.05 | 0.08 |
| Surprise Percentage | -121500% | -111910.7% | -25% | -43.4627% | 0% | 2.381% | -18.4211% | 22% | -4.2553% | -4.6512% | -13.1579% | 13.3333% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VOR
2026-02-23 13:29:14
Vor Bio, a clinical-stage biotechnology company, announced its participation in the 46th Annual TD Cowen Health Care Conference. The company will deliver a presentation on Monday, March 2, 2026, and host 1x1 investor meetings. This event highlights Vor Bio's ongoing efforts to advance its telitacicept program for autoimmune diseases.
2026-02-16 20:28:29
Vor Bio has issued inducement grants consisting of stock options for 6,959,013 shares and restricted stock units (RSUs) for 1,491,217 shares to seven new employees. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the employees' compensation packages, with vesting periods tied to continued employment. The biotechnology company is focused on the Phase 3 clinical development of telitacicept for autoimmune diseases.
2026-02-15 08:57:53
Vor Biopharma Inc. (NASDAQ:VOR) has received a "Moderate Buy" consensus rating from thirteen brokerage firms, with an average twelve-month price target of $66.1250. The ratings include one sell, five hold, six buy, and one strong buy recommendations. Several analysts have recently adjusted their ratings and price targets for the company.
2026-02-08 13:32:44
Vor Biopharma's shares surged after entering a global licensing agreement with Actinium Pharmaceuticals to develop and commercialize VOR33, a CD33-directed TIL therapy, for autoimmune diseases. This deal could bring Vor Biopharma up to $178 million in milestone payments and royalties.
2026-01-21 07:57:17
Vor Biopharma Inc. (NASDAQ:VOR) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average one-year target price of $66.1250. This rating is based on various analyst recommendations including buy, strong buy, hold, and sell ratings. Recent analyst activities show upgrades from firms like Robert W. Baird and Zacks Research, while a director also sold a significant number of shares.
2026-01-09 13:09:05
Citigroup has initiated coverage on Vor Biopharma (NASDAQ:VOR) with a "buy" rating and a $50 price target, suggesting a significant upside. Other analysts have also issued "buy" and "outperform" ratings, contributing to a consensus of "Moderate Buy" with a target of $66.13. Despite some recent insider selling, institutional investors hold a substantial portion of the company's stock.
